Free Trial
NASDAQ:MOLN

Molecular Partners Q3 2024 Earnings Report

Molecular Partners logo
$3.78 +0.03 (+0.80%)
As of 02:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Molecular Partners EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.63
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Molecular Partners Revenue Results

Actual Revenue
$0.79 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Molecular Partners Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Sunday, November 3, 2024
Conference Call Time
3:00PM ET

Upcoming Earnings

Molecular Partners' H1 2025 earnings is scheduled for Thursday, May 15, 2025

Earnings Documents

Molecular Partners Earnings Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
See More Molecular Partners Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Molecular Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Molecular Partners and other key companies, straight to your email.

About Molecular Partners

Molecular Partners (NASDAQ:MOLN), a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

View Molecular Partners Profile

More Earnings Resources from MarketBeat